Edition:
India

IRIDEX Corp (IRIX.OQ)

IRIX.OQ on NASDAQ Stock Exchange Global Market

4.16USD
14 Dec 2018
Change (% chg)

$-0.09 (-2.12%)
Prev Close
$4.25
Open
$4.24
Day's High
$4.25
Day's Low
$4.10
Volume
11,601
Avg. Vol
9,475
52-wk High
$9.48
52-wk Low
$4.10

Latest Key Developments (Source: Significant Developments)

IRIDEX Announces Q3 Revenue of $11.3 Million
Friday, 2 Nov 2018 

Nov 1 (Reuters) - IRIDEX Corp ::IRIDEX ANNOUNCES 2018 THIRD QUARTER FINANCIAL RESULTS AND RAISES FULL YEAR 2018 GUIDANCE.Q3 REVENUE $11.3 MILLION VERSUS $10.9 MILLION.QTRLY LOSS PER SHARE $0.26.EXPECTS G6 SYSTEM SHIPMENTS OF 430 TO 450 FOR FY.SEES FY TOTAL REVENUE OF $41 MILLION TO $42 MILLION.COMPANY ALSO RAISED LOWER END OF ITS 2018 G6 PROBE SHIPMENTS GUIDANCE TO A RANGE OF 44,000 TO 46,000.  Full Article

IRIDEX Announces Pricing Of Public Offering Of Common Stock
Friday, 14 Sep 2018 

Sept 14 (Reuters) - IRIDEX Corp ::IRIDEX ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 1.67 MILLION COMMON SHARES PRICED AT $6.00PER SHARE.  Full Article

Iridex Announces 2018 Second Quarter Results And Raises Full Year 2018 Guidance
Friday, 3 Aug 2018 

IRIDEX Corp ::IRIDEX ANNOUNCES 2018 SECOND QUARTER RESULTS AND RAISES FULL YEAR 2018 GUIDANCE.Q2 REVENUE ROSE 3 PERCENT TO $10.3 MILLION.SEES FY 2018 REVENUE $38 MILLION TO $41 MILLION.QTRLY LOSS PER SHARE $0.28.  Full Article

Iridex Issues Voluntary Recall Of Trufocus Lio Premiere Laser Indirect Ophthalmoscope
Saturday, 24 Feb 2018 

Feb 23 (Reuters) - Iridex Corp ::IRIDEX ISSUES VOLUNTARY RECALL OF TRUFOCUS LIO PREMIERE™ LASER INDIRECT OPHTHALMOSCOPE.IRIDEX CORP - REVISED ITS PRELIMINARY FINANCIAL RESULTS FOR Q4 AND FULL YEAR ENDED DECEMBER 30, 2017.IRIDEX CORP - RECALLED PRODUCTS WERE MANUFACTURED FROM MAY 26, 2017 TO NOVEMBER 6, 2017 AND DISTRIBUTED FROM JUNE 5, 2017 TO JANUARY 29, 2018.IRIDEX CORP - TOTAL REVENUE FOR Q4 OF 2017 IS EXPECTED TO BE $10.2 TO $10.3 MILLION.IRIDEX CORP - TOTAL REVENUE FOR 2017 IS EXPECTED TO BE $41.5 TO $41.6 MILLION.IRIDEX CORP - COMPANY HAS RECEIVED REPORTS OF THREE ADVERSE EVENTS OCCURRING DURING PROCEDURES IN WHICH TRUFOCUS LIO PREMIERE WAS USED.  Full Article

Societe Quantel Issues Response To Iridex Press Release​
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Societe Quantel Sa ::‍QUANTEL ISSUES RESPONSE TO IRIDEX PRESS RELEASE​.‍WE DO NOT ANTICIPATE ANY DISRUPTION TO OUR ONGOING COMMERCIAL PROGRESS​.SAYS BELIEVES ‍IRIDEX'S ACTION IS WITHOUT MERIT​.‍QUANTEL INTENDS TO VIGOROUSLY DEFEND ITSELF AGAINST CLAIMS​.  Full Article

Iridex Corp ‍Filed Lawsuit Against Quantel Medical S.A
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Iridex Corp ::IRIDEX CORP - ‍FILED LAWSUIT AGAINST QUANTEL MEDICAL S.A., QUANTEL USA, QUANTEL, S.A. IN U.S. DISTRICT COURT FOR NORTHERN DISTRICT OF CALIFORNIA​.  Full Article

Iridex Corp reports qtrly loss per share $0.27‍​
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Iridex Corp :Iridex announces 2017 third quarter financial results.Q3 revenue rose 11 percent to $10.9 million.Iridex Corp - ‍Iridex reiterates its previously provided estimate for revenue, and g6 system and g6 probe shipments for full year 2017​.Iridex Corp - qtrly loss per share $0.27‍​.  Full Article